Skip to content
Search

Latest Stories

Medicines optimisation and pharmacy collaboration key to improved patient outcomes, report finds

Medicines optimisation and pharmacy collaboration key to improved patient outcomes, report finds
Outcomes-centred contractual frameworks and greater stakeholder collaboration between the NHS and pharmacy sector is required to unlock value-based medicines optimisation

A recently published report on medicines optimisation highlights the urgent need for transformative changes across all pharmacies to unlock their full potential in delivering integrated care.

The report by Public Policy Projects (PPP) is first of the four in the series that emphasises the significant benefits that medicines optimisation can bring to integrated care systems (ICSs).


This includes reducing health inequalities and improving population health.

Pointing to the "untapped opportunity" that medicines optimisation presents for ICSs facing financial challenges, the report underscores the vital role of pharmacies in enhancing patient outcomes.

The launch of the Pharmacy First services has already demonstrated the essential contribution of pharmacies to the health and care system.

With "medicines being the second highest cost to the NHS," the report recommends ways  "to achieve better value for money while improving patient outcomes".

However, it also notes that further support is necessary to maximise the value of medicines optimisation, which includes improving patient flow, reducing hospital admissions, and enhancing community care.

It also advocates for new contractual frameworks that enable pharmacies to deliver patient-centric and outcomes-based medicines optimisation interventions.

Recommending greater collaboration between the NHS and industry, the report underscores that "the NHS’s transition to a systemised approach has introduced barriers to collaboration, complicating the delivery of pharmacy priorities."

The establishment of ICSs in 2022 and the subsequent systemisation of medicine optimisation have created challenges for pharmacies.

Moreover, the restructuring of medicines teams and leadership positions has complicated collaboration across all parts of the system and with industry partners.

This situation is aggravated by broader issues such as insufficient pharmacy leadership, workforce shortages, and inadequate career development opportunities.

These challenges are compounded by the fact that ICSs vary in their maturity and are under increasing financial pressure.

Yousaf Ahmad, Chief Pharmacist at NHS Frimley, commented, "As we navigate the complexities of integrated care delivery, this report highlights a significant opportunity for pharmacy to contribute in a more meaningful way.

"Through more effective collaboration to deliver medicines optimisation, pharmacy has the potential to drive positive patient outcomes and produce value-based efficiencies."

Calling to the PPP report "thoughtful" , Michael Lennox, Local Integration Lead for the National Pharmacy Association (NPA), said:

"In our own recent round table deep-dive on medicines optimisation it was clear that there is a strong consensus that community pharmacy can expand our role to deliver a marked uplift in medicines optimisation.

"This will deliver benefits to cost-effective patient care, provided a re-imagination of our national contract paves the way, and local systems embrace and enable these opportunities."

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less